{"id":"W4313038059","doi":"10.1136/ijgc-2022-esgo.539","title":"2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Interquartile range; Adverse effect; Ovarian cancer; Gastroenterology; Population; Phases of clinical research; Progression-free survival; Cancer; Oncology; Clinical trial; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002366749,0.0007113595,0.001729574,0.0003973693,0.0002794136,0.0009903111,0.0004369779,0.00088226,0.003877538],"category_scores_gemma":[0.001211146,0.000408848,0.001804155,0.0003841005,0.0006009266,0.0007135304,0.0003092006,0.001883648,0.0005921453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007531827,"about_ca_system_score_gemma":0.001018268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006080105,"about_ca_topic_score_gemma":0.002897247,"domain_scores_codex":[0.9993432,0.0003494899,0.00003732933,0.00009262574,0.00006703759,0.0001103205],"domain_scores_gemma":[0.999421,0.0001441784,0.000134816,0.00006412766,0.00005773231,0.0001780288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.757109,0.01461111,0.01042473,0.00116613,0.005285114,0.0001604335,0.0002466992,0.004106907,0.06530039,0.0005726878,0.002634733,0.1383819],"study_design_scores_gemma":[0.3905076,0.5274524,0.04807976,0.0001202298,0.004724915,0.0004631022,0.0001760085,0.002984178,0.01324639,0.0006166433,0.01154413,0.00008474533],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922219,0.003390333,0.000459342,0.0003679487,0.00008496616,0.0006409635,0.0009488767,0.00006199277,0.001823728],"genre_scores_gemma":[0.9929172,0.001264799,0.0008156448,0.0004503873,0.00005133815,0.0005776605,0.002042211,0.00002615852,0.001854687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003877538,"threshold_uncertainty_score":0.0129717,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09066084088177515,"score_gpt":0.3777070812159118,"score_spread":0.2870462403341366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}